THALES
Thales, the leading global technology and security provider, today announced Passwordless 360°, a new concept for passwordless authentication which offers Thales customers the broadest coverage of passwordless function across multiple types of users and assurance levels. Passwordless 360° has the flexibility to let companies use the latest technologies like FIDO passkeys, while also making the most of previous investments they might have made in passwordless technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605617393/en/
©KuppingerCole
End users are increasingly frustrated with the number of passwords they’re asked to use, as well as the rules in place around their complexity. With the average person having as many as 100 to manage, users seek workarounds to get by – choosing passwords that are easier to remember or reusing the same password across multiple services.
Passwordless 360° provides a complete set of tools that let organizations use passwordless authentication across a wide range of applications - from secure access to personal and work devices, to legacy and modern web resources. This helps keep the costs of making the move to passwordless down by being able to use one system – as well as increasing the likelihood that employees, customers and suppliers will use it. By removing the need to use traditional passwords it also eliminates the associated security risks through theft and phishing. Passwordless 360° can also meet the individual risk management requirements an organization might have, adhering to NIST requirements no matter where the passkeys are stored.
Sitting alongside the existing Thales OneWelcome Identity Platform that serves as the foundation for passwordless policies, the Passwordless 360° concept includes:
- Support for passkeys in the OneWelcome Identity Platform
- Passwordless Windows Logon, a true passwordless user experience that replaces passwords with ways for users to identify themselves, offering convenience and security benefits.
- SafeNet FIDO Key Manager, a way of helping users manage the several FIDO keys they might be using themselves, reducing administration costs for organizations.
- FIDO Authenticator Lifecycle Management, developed in partnership with identity management software company Versasec. This tool lets organizations manage FIDO tokens and lets larger enterprises make the move to the modern FIDO standard at the scale needed.
The announcement comes as Thales has been named an Overall, Product, Innovation and Market Leader in KuppingerCole’s latest Leadership Compass on Passwordless Authentication for Consumers, with the platform praised for offering a versatile set of identity applications encompassing a wide range of authentication methods to meet organizations’ needs.
Alejandro Leal, Research Analyst at KuppingerCole commented: “Overall, Thales offers a comprehensive solution that enables organizations to improve their identity management practices, adapt to evolving technologies, and effectively secure their systems and data. Organizations in highly regulated industries and security-conscious organizations in both the public and private sectors that require strong authentication options should consider the OneWelcome Identity Platform.”
About Thales Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity. It develops products and solutions that help make the world safer, greener and more inclusive. The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G. Thales has close to 81,0001 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion. _______________________________ 1 Excluding Transport business, which is being divested |
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605617393/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
